Rapid strides have been made in the field of hematology, and
advances in immune thrombocytopenic purpura (ITP) management
are no exception. From idiopathic to immune, the
changed nomenclature is itself a testimonial to the growing
awareness and improvements in the management of ITP. We
discuss the pathophysiology, clinical presentation, and current
management of this common pediatric disorder and summarize
current guidelines for ITP treatment.